When it comes to biotech in 2021, the author of today’s article expects the sector to remain very attractive, noting that “Valuations are quite reasonable and earnings have steadily increased. The leading stocks in the sector have high-margins and above-average revenue growth. Finally, the total addressable market for effective treatments continues to expand.” And while a diversified ETF is one way to play biotech’s continued outperformance, he recommends three specific biotech stocks with significant upside. For these three stocks, CLICK HERE.